Eli Lilly lets Hims & Hers sell Zepbound and Foundayo
Hims & Hers Health agreed not to sell compounded versions or knockoffs of Lilly obesity drugs under the deal. Self-pay prices start at $149 a month for the Foundayo pill and $299 a month for injectable Zepbound.
Eli Lilly announced the deal on Friday. Until now, the telehealth platform only sent patients to LillyDirect, Lilly's cash-pay platform. Reports said self-pay prices on Hims & Hers match those on LillyDirect.
Ilya Yuffa, president of Lilly USA, said getting Lilly medicine on the Hims & Hers platform was not fully straightforward before the deal. He said any friction point for consumers raises the chance that they give up. Lilly said 40% to 45% of Zepbound sales go through self-pay channels.
Danish rival Novo Nordisk already sells Wegovy and Ozempic through Hims & Hers. Its Wegovy pill starts at $149 a month and its Wegovy injector pen at $199 a month. Hims & Hers shares rose more than 7% in premarket trading.
Analysts said Hims & Hers may gain next year if employers drop cover for weight-loss drugs to cut costs. Lilly raised its full-year revenue forecast by $5bn last week.
Key facts
- Who
- Ilya Yuffa (president of Lilly USA); Eli Lilly (drugmaker that struck the deal); Hims & Hers Health (telehealth company selling the drugs); Novo Nordisk (Danish rival already selling Wegovy and Ozempic through Hims & Hers)
- What
- Eli Lilly said on Friday that Hims & Hers Health will sell Zepbound and Foundayo directly on its telehealth platform, previously available only via Lilly's LillyDirect cash-pay platform. Under the deal Hims & Hers agreed not to sell compounded versions or knockoffs of Lilly obesity medications; self-pay prices match LillyDirect.
- When
- 6 November 2026
- Status
- Reported